Protagenic Therapeutics to Host Webinar with Dr. Maurizio Fava for its Lead Molecule PT00114 on Tuesday, July 13th at 10:00 AM ET
Protagenic Therapeutics (Nasdaq: PTIX) will host a webinar on July 13, 2021, at 10:00 AM ET, to discuss PT00114, a potential treatment for stress-related disorders such as Depression, PTSD, Anxiety, and Addiction. The webinar features Dr. Maurizio Fava, a leading psychiatrist and principal investigator for the upcoming Phase 1/2a trial. He will provide insights into the clinical development of PT00114, a peptide aimed at regulating stress response in the brain. Interested participants can contact James Carbonara at Hayden IR for registration details.
- None.
- None.
NEW YORK, July 06, 2021 (GLOBE NEWSWIRE) -- Protagenic Therapeutics, Inc. (Nasdaq: PTIX) a biopharmaceutical company focused on developing therapies to treat stress-related neurologic disorders, today announced that it will host a key opinion leader (KOL) webinar focused on PT00114 for the regulation of stress in patients with Depression, PTSD, Anxiety and Addiction on Tuesday, July 13 at 10:00AM ET.
The webinar will feature a presentation by Dr. Maurizio Fava, Psychiatrist-in-Chief in the Department of Psychiatry at Massachusetts General Hospital (MGH), who is serving as principal investigator in Protagenic’s upcoming Phase 1/2a clinical trial. Protagenic’s management team will also provide an overview of the clinical development program for PT00114, which is known scientifically as teneurin C-terminal associated peptide (TCAP), a naturally occurring peptide responsible for regulation of stress response in the brain.
Dr. Maurizio Fava is an international leader in the field of depression. Along with serving as Psychiatrist-in-Chief in the Department of Psychiatry at Massachusetts General Hospital, he is also Director of the Division of Clinical Research, Mass General Research Institute, Associate Dean for Clinical & Translational Research, and Slater Family Professor of Psychiatry at Harvard Medical School. In 2007, he founded and is now Executive Director of the Mass General Psychiatry Clinical Trials Network and Institute (“CTNI”), the first academic contract research organization (“CRO”) specialized in planning and coordination of multi-center clinical trials in psychiatry. He has authored or co-authored more than 800 original articles published in medical journals with international circulation, edited eight books, and published more than 50 chapters and over 600 abstracts. Dr. Fava earned his medical degree from the University of Padua.
To register for the webinar, contact James Carbonara at Hayden IR, Office:(646)-755-7412, or James@haydenir.com.
About Protagenic Therapeutics, Inc.
Protagenic Therapeutics, Inc. (Nasdaq: PTIX) is a pre-clinical biopharmaceutical company endeavoring to develop first-in-class neuro-active peptides into human therapeutics to treat several stress related disorders. For more information, visit http://www.protagenic.com.
Forward-Looking Statements
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding Protagenic Therapeutics’ product candidates and pre-clinical development and clinical trial plans and activities. Forward-looking statements include words such as "expects," "anticipates," "intends," "plans," "could," "believes," "estimates" and similar expressions. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, our ability to obtain additional capital to meet our liquidity needs on acceptable terms, or at all, including the additional capital which will be necessary to complete the pre-clinical testing and eventual clinical trials of our product candidates; our ability to successfully complete research and further development and commercialization of our product candidates; the uncertainties inherent in pre-clinical and clinical testing; the timing, cost and uncertainty of obtaining regulatory approvals; our ability to protect the Company's intellectual property; the loss of any executive officers or key personnel or consultants; competition; changes in the regulatory landscape or the imposition of regulations that affect the Company's products; and the other factors described under the Risk Factors section of our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission.. Protagenic Therapeutics cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and Protagenic undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.
Analyst Contact:
Alexander K. Arrow, MD, CFA
Chief Financial Officer
213-260-4342
alex.arrow@protagenic.com
Media Contact:
James Carbonara
Hayden IR
(646)-755-7412
james@haydenir.com
FAQ
What is the purpose of the Protagenic Therapeutics webinar on July 13, 2021?
Who is presenting at the Protagenic webinar on PT00114?
What is PT00114 in the context of Protagenic Therapeutics?
When is the Protagenic Therapeutics webinar scheduled?
How can I register for the Protagenic Therapeutics webinar?
